86932 Federal Register / Vol. 85, No. 251 / Thursday, December 31, 2020 / Notices 

5See, e.g., Statement of Commissioner Maureen 

K. Ohlhausen, In the Matter of Health Discovery 

Corporation and FTC v. Avrom Boris Lasarow, et al. 

(Feb. 2015), https://www.ftc.gov/public-statements/ 

2015/02/dissenting-statement-commissionermaureen-k-ohlhausen-matter-health; Statement of 

Commissioner Joshua D. Wright, FTC v. Kevin 

Wright; HCG Platinum, LLC; and Right Way 

Nutrition, LLC (Dec. 2014), https://www.ftc.gov/ 

public-statements/2014/12/statementcommissioner-joshua-d-wright-federal-tradecommission-v-kevin; Statement of Commissioner 

Joshua D. Wright, In the Matter of GeneLink, Inc., 

and foru International Corporation (January 2014), 

https://www.ftc.gov/public-statements/2014/01/ 

statement-commissioner-joshua-d-wright-mattergenelink-inc-foru; Statement of Commissioner 

Maureen K. Ohlhausen Dissenting in Part and 

Concurring in Part, In the Matter of GeneLink, Inc. 

and foru International Corporation (January 2014), 

https://www.ftc.gov/public-statements/2014/01/ 

statement-commissioner-maureen-k-ohlhausendissenting-part-concurring-part; Dissenting 

Statement of Commissioner Maureen K. Ohlhausen, 

FTC v. Springtech 77376, et al. (July 2013), https:// 

www.ftc.gov/public-statements/2013/07/dissentingstatement-commissioner-maureen-k-ohlhausen; see 

also J. Howard Beales, III and Timothy J. Muris, In 

Defense of the Pfizer Factors, George Mason Law & 

Economics Research Paper No. 12–49 (May 2012), 

available at: https://papers.ssrn.com/sol3/ 

papers.cfm?abstract_id=2087776. 

6See Statement of Commissioner Rohit Chopra 

Regarding the Cannabidiol (CBD) Enforcement 

Actions (Dec. 17, 2020). 

information, may diminish incentives to 

conduct research, and could chill 

manufacturer incentives to introduce 

new products to the market.5 And I 

agree with the observation of my 

colleague Commissioner Chopra in his 

statement that ‘‘[b]aseless claims give 

patients false hope, improperly increase 

or divert their medical spending, and 

undermine ‘a competitor’s ability to 

compete’ on honest attributes.’’ 6

Although I support these cases, I hope 

that the Commission’s actions here, 

which challenge wholly unsubstantiated 

disease claims, do not discourage 

research into the potential legitimate 

benefits of CBD and a wide array of 

other products. In addition, going 

forward, I urge the Commission to focus 

our scarce resources on marketers that 

make strong, express claims about 

diseases and serious health issues with 

little to no scientific support and engage 

in deceptive practices that cause 

substantial consumer injury. 

[FR Doc. 2020–29003 Filed 12–30–20; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30 Day–21–1277] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled The Childcare 

Survey of Activity and Wellness (C– 

SAW) Pilot Study to the Office of 

Management and Budget (OMB) for 

review and approval. CDC previously 

published a ‘‘Proposed Data Collection 

Submitted for Public Comment and 

Recommendations’’ notice on October 

30, 2020 to obtain comments from the 

public and affected agencies. CDC 

received one public comment related to 

the previous notice. This notice serves 

to allow an additional 30 days for public 

and affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary for the 

proper performance of the functions of the 

agency, including whether the information 

will have practical utility; 

(b) Evaluate the accuracy of the agencies 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and assumptions 

used; 

(c) Enhance the quality, utility, and clarity 

of the information to be collected; 

(d) Minimize the burden of the collection 

of information on those who are to respond, 

including, through the use of appropriate 

automated, electronic, mechanical, or other 

technological collection techniques or other 

forms of information technology, e.g., 

permitting electronic submission of 

responses; and 

(e) Assess information collection costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

The Childcare Survey of Activity and 

Wellness (C–SAW) Pilot Study (OMB 

Control No. 0920–1277, Exp. 12/31/ 

2020)—Revision—National Center for 

Chronic Disease Prevention and Health 

Promotion (NCCDPHP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention (CDC) work to promote 

optimal nutrition, physical activity, and 

wellness in early care and education 

(ECE) facilities for children 0–5 years of 

age. Data collected from this pilot 

survey will be used to understand the 

current practices of ECE centers in a 

representative sample in four states. The 

survey will also be used to inform the 

development of a potential national 

surveillance system. 

A sample of approximately 1,266 ECE 

centers across four states will be 

selected to participate in this one-time 

data collection effort. However, it is 

estimated that approximately 10% of 

the original sample will be out of 

business or otherwise ineligible yielding 

an actual sample of 1,140 ECEs to be 

recruited. Each center will receive a 

recruitment letter introducing the 

survey, and instructions for completing 

the survey. It is anticipated that most 

responses will be submitted through the 

web. However, paper surveys will be 

available upon request. It is also 

anticipated that the response rate will 

be approximately 55% based on a 

review of recent surveys of childcare 

centers conducted by the Federal 

government. Thus, we anticipate the 

number of completed surveys to be 627. 

CDC requests approval for a two year 

period with an estimated 513 total 

Burden Hours. Participation in this 

study is completely voluntary and there 

are no costs to the respondent other 

than their time. 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 85, No. 251 / Thursday, December 31, 2020 / Notices 86933 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

ECE Director or Administrator ........................ Recruitment Letter .......................................... 1,140 1 5/60 

ECE Director or Administrator ........................ Web/Mail Survey ............................................ 627 1 40/60 

Jeffery M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2020–28982 Filed 12–30–20; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Requirement for Negative PreDeparture COVID–19 Test Result for All 

Airline Passengers Arriving Into the 

United States From the United 

Kingdom 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of Agency Order. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), a 

component of the U.S. Department of 

Health and Human Services (HHS), 

announces an Agency Order requiring 

negative pre-departure COVID–19 test 

results for all airline passengers arriving 

into the United States from the United 

Kingdom (UK). This Order is issued to 

preserve human life; prevent the further 

introduction, transmission, and spread 

of the virus that causes COVID–19 into 

the United States, including new virus 

variants; preserve the health and safety 

of airline crew members, passengers, 

airport personnel, and communities; 

and preserve hospital, healthcare, and 

emergency response resources within 

the United States. 

DATES: This Order was effective 

December 27, 2020 at 7:01 p.m. EST 

(12:01 a.m. December 28, 2020 GMT). 

See SUPPLEMENTARY INFORMATION for the 

conditions under which the Order will 

expire. 

FOR FURTHER INFORMATION CONTACT: 

Jennifer Buigut, Division of Global 

Migration and Quarantine, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H16–4, Atlanta, 

GA 30329. Email: dgmqpolicyoffice@

cdc.gov. 

SUPPLEMENTARY INFORMATION: On 

December 14, 2020, Public Health 

England announced that a new variant 

of SARS-CoV–2 had been identified 

across the southeast of England (i.e., 

Kent and the surrounding areas). While 

it is known and expected that viruses 

change through mutation leading to the 

emergence of new variants, preliminary 

analysis in the UK suggests that this 

SARS–CoV–2 variant may be more 

transmissible than previously 

circulating variants. Pre-departure 

testing may detect travelers infected 

with SARS–CoV–2 before they initiate 

their travel and may reduce the risk of 

transmission. Therefore, urgent efforts 

are needed to mitigate the potential 

spread of this new virus variant into the 

United States. 

This Order establishes requirements 

for (1) airlines arriving into the United 

States from the UK; and (2) passengers 

departing the United Kingdom with a 

final destination in the United States. 

A copy of the Order and Attachment 

A are provided below and a copy of the 

signed order can be found at https://

www.cdc.gov/quarantine/testingrequirement-for-arriving-UK-airtravelers.html. 

Centers for Disease Control and 

Prevention Department of Health and 

Human Services 

Order Under Section 361 of the Public 

Health Service Act (42 U.S.C. 264) and 

42 Code of Federal Regulations 71.20 & 

71.31(b) 

Requirement for Negative Pre– 

Departure Covid–19 Test Result for All 

Airline Passengers Arriving Into the 

United States From the United Kingdom 

(UK) 

Summary 

Pursuant to 42 CFR 71.20 and as set 

forth in greater detail below, this Notice 

and Order prohibit the introduction into 

the United States of any airline 

passenger departing from the UK unless 

the passenger has a negative predeparture test result for COVID–19. The 

test must be a viral test that was 

conducted on a specimen collected 

during the 3 calendar days preceding 

the flight’s departure (Qualifying Test). 

Passengers must retain written or 

electronic documentation reflecting the 

negative Qualifying Test result 

presented to the airline and produce 

such results upon request to any U.S. 

government official or a cooperating 

state or local public health authority. 

Pursuant to 42 CFR 71.31(b) and as set 

forth in greater detail below, this Notice 

and Order constitutes a controlled free 

pratique to any airline with an aircraft 

arriving into the United States from the 

UK. Pursuant to the controlled free 

pratique, the airline must comply with 

the following conditions in order to 

receive permission for the aircraft to 

enter and disembark passengers in the 

United States: 

• Airline must verify that every 

passenger—2 years of age or older— 

onboard the flight has attested to having 

received a negative Qualifying Test 

result. 

• Airline must confirm that every 

passenger onboard the aircraft has 

documentation reflecting a negative 

Qualifying Test result. 

Statement of Intent 

This Order shall be interpreted and 

implemented in a manner as to achieve 

the following paramount objectives: 

• Preservation of human life; 

• Preventing the further introduction, 

transmission, and spread of the virus 

that causes COVID–19 into the United 

States, including new virus variants; 

• Preserving the health and safety of 

airline crew members, passengers, 

airport personnel, and communities; 

and 

• Preserving hospital, healthcare, and 

emergency response resources within 

the United States. 

Definitions 

Airline shall have the same definition 

as under 42 CFR 71.1(b). 

Attest/Attestation means having 

completed the attestation in Attachment 

A. Such attestation may be completed in 

written or electronic form. The 

attestation is a statement, writing, entry, 

or other representation under 18 U.S.C. 

1001. 

Confirm that every passenger onboard 

the aircraft has documentation 

reflecting a negative Qualifying Test 

result means confirmation that: 

(1) The personal identifiers (e.g., 

name and date of birth) on the 

Qualifying Test result match the 


khammond on DSKJM1Z7X2PROD with NOTICES